Roche has completed its acquisition of TIB Molbiol Group, which will continue to operate as a subsidiary within Roche’s diagnostics division.
Roche and TIB Molbiol will build on their capabilities for the rapid development of assays for emerging pathogens and potential health threats, such as infectious diseases, Roche said. The two companies have collaborated for more than 20 years to address healthcare needs including biological threats, such as SARS, anthrax, avian influenza virus H5N1, MERS, the novel influenza virus H1N1 swine, Ebola virus, Zika virus, and most recently, SARS-CoV-2.
TIB Molbiol has more than 45 CE-IVD assays and more than 100 research-use-only assays. In addition to infectious diseases, the company also has assays for inherited genetic and somatic mutation testing, hematology, and transplantation medicine.
